A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY OF KITE-753 VERSUS AXICABTAGENE CILOLEUCEL IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY LARGE B-CELL LYMPHOMA AFTER FIRST-LINE THERAPY

Registry ID

KT-US-740-0603

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

KITEPHARMA INC

Start date

2026-05-10

Last update

2026-04-10

Conditions

• LARGE B-CELL LYMPHOMA

Related clinical trials

• A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

View on source registry